Case Study: EGFR and ALK in NSCLC Trials
Case Study: EGFR and ALK in NSCLC Trials Lessons from EGFR and ALK Targeted Therapy Trials in NSCLC Introduction to EGFR and ALK in Non-Small Cell Lung Cancer Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases globally. Two of the most clinically significant biomarkers in NSCLC are the epidermal growth…